Anatomic Site
You have full text access to this OnlineOpen article
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia (pages 1203–1209)Alvaro Aguayo, Jorge Cortes, Deborah Thomas, Sherry Pierce, Michael Keating and Hagop Kantarjian
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3
L-asparaginase in combination with methotrexate has synergistic antileukemia activity in patients with acute lymphoblastic leukemia (ALL). A new formulation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, has a longer half-life and is less immunogenic. A combination of methotrexate, vincristine, PEG-asparaginase, and prednisone was used to treat 32 patients with refractory or recurrent ALL. Seven patients (22%) achieved a complete remission (CR). The median duration of the CR was 16 weeks and the median survival of the patients was 12 weeks.
You have full text access to this OnlineOpen article
Herpes lymphadenitis in association with chronic lymphocytic leukemia (pages 1210–1215)John P. T. Higgins and Roger A. Warnke
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1210::AID-CNCR16>3.0.CO;2-8
Herpes lymphadenitis may be seen in association with chronic lymphocytic leukemia. The infection may follow an indolent course even if untreated.
You have full text access to this OnlineOpen article
Primary refractory and relapsed adult acute lymphoblastic leukemia : Characteristics, treatment results, and prognosis with salvage therapy (pages 1216–1230)Deborah A. Thomas, Hagop Kantarjian, Terry L. Smith, Charles Koller, Jorge Cortes, Susan O'Brien, Francis J. Giles, James Gajewski, Sherry Pierce and Michael J. Keating
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O
A review of 314 patients treated for relapsed or refractory acute lymphoblastic leukemia identified factors associated with poor outcomes: older age, short duration of first complete response, and circulating blasts. Despite favorable responses in some subgroups, the overall results with therapy were uniformly poor, highlighting the need to identify strategies to improve first remission duration and the need for further research of new agents.
You have full text access to this OnlineOpen article
Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone : Analysis of the MRC AML 10 trial (pages 1231–1239)Maggie Watson, Keith Wheatley, Georgina A. Harrison, Robert Zittoun, Richard G. Gray, Alan H. Goldstone and Alan K. Burnett
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1231::AID-CNCR18>3.0.CO;2-Y
Data from the current study showed that bone marrow transplantation (BMT) had an adverse impact on sexual health and fertility compared with consolidation chemotherapy (CCT) in patients with acute myeloid leukemia (AML) who were included in the AML 10 trial. These aspects of quality of life were assessed ≥1 year after the completion of therapy in patients whose disease remained in remission. Because the survival benefits of BMT over CCT are quite modest, these iatrogenic effects should be considered when deciding on appropriate treatment for leukemia and follow-up management for patients whose AML is in first complete remission.
You have full text access to this OnlineOpen article
Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis (pages 1240–1245)Helen H. Wang, Timothy Myers, Lori J. Lach, Chung-cheng Hsieh and Marshall E. Kadin
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1240::AID-CNCR19>3.0.CO;2-X
Patients with lymphomatoid papulosis were found to have an increased risk for both lymphoid and nonlymphoid malignancies.
You have full text access to this OnlineOpen article
Chromosome rearrangement at 17q25 and Xp11.2 in alveolar soft-part sarcoma : A case report and review of the literature (pages 1246–1250)Susumu Joyama, Takafumi Ueda, Kiichi Shimizu, Ikuo Kudawara, Masayuki Mano, Hiroko Funai, Koichi Takemura and Hideki Yoshikawa
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1246::AID-CNCR20>3.0.CO;2-4
This case report documents a clonal chromosome abnormality of der(17)t(X;17)(p11.2;q25) in alveolar soft-part sarcoma (ASPS), suggesting that further molecular analyses focused on 17q25 and Xp11.2 are of interest and could help to elucidate the pathogenesis of ASPS.
You have full text access to this OnlineOpen article
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma (pages 1251–1257)Nuhad K. Ibrahim, Zia Rahman, Vicente Valero, Jie Willey, Richard L. Theriault, Aman U. Buzdar, James L. Murray III, Robert Bast and Gabriel N. Hortobagyi
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1251::AID-CNCR21>3.0.CO;2-F
Due to toxicity, a revised maximum tolerated dose for continuous infusion vinorelbine is proposed. The current dosing schedule did not offer an advantage in either response rates or survival compared with the weekly vinorelbine bolus injection in doxorubicin-resistant and paclitaxel-resistant patients.
You have full text access to this OnlineOpen article
Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation (pages 1258–1262)John E. Mignano, Marianna L. Zahurak, Anuradha Chakravarthy, Steven Piantadosi, William C. Dooley and Irene Gage
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1258::AID-CNCR22>3.0.CO;2-S
Axillary lymph node extranodal soft tissue extension does not appear to correlate with an increased risk of axillary recurrence, even without axillary irradiation.
You have full text access to this OnlineOpen article
P-cadherin expression in breast carcinoma indicates poor survival (pages 1263–1272)Alejandro Peralta Soler, Karen A. Knudsen, Hernando Salazar, Aaron C. Han and Albert A. Keshgegian
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.0.CO;2-2
The expression of cadherin and catenin cell-cell adhesion proteins was analyzed in 183 paraffin embedded breast carcinoma tissue sections by immunohistochemistry. The expression of P-cadherin was found to correlate with poor survival of patients.
You have full text access to this OnlineOpen article
Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females : Clinical observations and histopathologic features (pages 1273–1284)Boel K. Ragnarsson-Olding, Lena R. Kanter-Lewensohn, Bengt Lagerlöf, Bo R. Nilsson and Ulrik K. Ringborg
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z
To the authors' knowledge, this report encompasses the largest series of vulvar melanomas published. It highlights the clinical and histopathologic features that are at variance with cutaneous melanoma, and shows differences among tumors in various compartments of the vulva.
You have full text access to this OnlineOpen article
Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females : Predictors of survival (pages 1285–1293)Boel K. Ragnarsson-Olding, Bo R. Nilsson, Lena R. Kanter-Lewensohn, Bengt Lagerlöf and Ulrik K. Ringborg
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1285::AID-CNCR25>3.0.CO;2-P
Tumor thickness, ulceration, and macroscopic amelanosis, but not treatment mode, were identified as the most important predictors of tumor specific survival.
You have full text access to this OnlineOpen article
Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma (pages 1294–1298)Tak Hong Cheung, Tony Kwok Hung Chung, Cho Sun Poon, Garrett M. Hampton, Vivian W. Wang and Yick Fu Wong
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1294::AID-CNCR26>3.0.CO;2-O
Frequent loss of heterozygosity (LOH) on chromosome 1 is observed in cervical carcinoma. This suggests that inactivation of tumor suppressor genes is important in the tumorigenesis of this disease. Significantly higher frequencies of LOH found in Stage III and IV disease compared with Stage I and II suggest that these chromosomal changes are late events related to tumor progression.
You have full text access to this OnlineOpen article
Characterization of Type I collagen synthesis and maturation in uterine carcinosarcomas (pages 1299–1306)Saila Kauppila, Frej Stenbäck, Barry M. Kacinski, Maria-Luisa Carcangiu, Juha Risteli and Leila Risteli
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1299::AID-CNCR27>3.0.CO;2-6
Type I (pro)collagen synthesis and corresponding protein maturation were studied in uterine carcinosarcomas by in situ hybridization and immunohistochemistry. The undifferentiated cells of uterine carcinosarcomas are capable of producing their own stroma with irregularly arranged collagen bundles.
You have full text access to this OnlineOpen article
Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma (pages 1307–1313)Shinya Sato, Junzo Kigawa, Yukihisa Minagawa, Makoto Okada, Muneaki Shimada, Masakuni Takahashi, Shunji Kamazawa and Naoki Terakawa
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1307::AID-CNCR28>3.0.CO;2-F
p53-dependent apoptosis in tumors is strongly related to chemosensitivity in epithelial ovarian carcinoma.
You have full text access to this OnlineOpen article
The age of the urologist affects the postoperative care of prostate carcinoma patients (pages 1314–1321)Diana Y. Tsai, Katherine S. Virgo, John W. Colberg, David K. Ornstein, Eric T. Johnson, Danny Chan and Frank E. Johnson
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1314::AID-CNCR29>3.0.CO;2-K
Patient management strategies utilized by urologists caring for prostate carcinoma patients after radical prostatectomy vary appreciably. A survey of urologists was used to determine the reasons for variation in practices. The age of the practitioner was found to have a significant effect on the management of at-risk patients, although the effect was small.
You have full text access to this OnlineOpen article
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma : Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide (pages 1322–1328)Peter J. Hoskin, Michelle I. Saunders and Stanley Dische
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1322::AID-CNCR30>3.0.CO;2-E
Sequential cohorts of patients treated with radical radiotherapy for bladder carcinoma using attempts at hypoxia modification were analyzed. The current approach using accelerated radiotherapy, carbogen, and nicotinamide has high local control rates compared with previous experience with no increase in morbidity. The authors propose Phase III trials to test this approach further.
You have full text access to this OnlineOpen article
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma (pages 1329–1334)William K. Oh, Judith Manola, Jerome P. Richie, Kevin R. Loughlin and Philip W. Kantoff
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1329::AID-CNCR31>3.0.CO;2-R
In the current study the treatment of muscle invasive or metastatic urothelial carcinoma with methotrexate, cisplatin, 5-fluorouracil, and leucovorin was found to be associated with a 63% response rate and moderate toxicity.
You have full text access to this OnlineOpen article
KDR activation in astrocytic neoplasms (pages 1335–1341)Rona S. Carroll, Jianping Zhang, Lorenzo Bello, Michael B. Melnick, Taka Maruyama and Peter McL Black
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO;2-Z
In this study the authors determined the activation state of the vascular endothelial growth factor receptor, KDR, in all grades of astrocytic neoplasms using an antibody that recognizes the phosphorylation state of tyrosines 1054/1059 in the receptor. Immunoblotting with this antibody shows that the receptor is phosphorylated constitutively within multiple fresh surgical specimens of glioblastomas (70%) and anaplastic gliomas (15%), but not in low grade gliomas. This strongly supports the hypothesis that the onset of angiogenesis is an important event during disease progression in gliomas.
You have full text access to this OnlineOpen article
Significantly lower incidence of cancer among patients with Huntington disease : An apoptotic effect of an expanded polyglutamine tract? (pages 1342–1346)S. Asger Sørensen, Kirsten Fenger and Jørgen H. Olsen
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1342::AID-CNCR33>3.0.CO;2-3
The incidence of cancer was significantly lower among 694 patients with Huntington disease (HD) compared with 695 healthy relatives and population estimates. The authors of this study hypothesize that this was due to an apoptotic effect of the expanded polyglutamine tract in the protein encoded by the HD gene.
You have full text access to this OnlineOpen article
Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis (pages 1347–1353)Timothy F. Witham, Melanie B. Fukui, Carolyn Cidis Meltzer, Richard Burns, Douglas Kondziolka and Michael E. Bozik
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1347::AID-CNCR34>3.0.CO;2-M
The available literature regarding the use of intrathecal chemotherapy for the treatment of patients with ependymal or leptomeningeal extension of malignant glioma is scant. Intrathecal therapy with thiotriethylenephosphoramide delivered via a ventricular reservoir system should be considered when patients with malignant glioma present with ependymal or leptomeningeal extension.
You have full text access to this OnlineOpen article
Tissue factor expressed in pituitary adenoma cells contributes to the development of vascular events in pituitary adenomas (pages 1354–1361)Toru Nishi, Tomoaki Goto, Hideo Takeshima, Kazuya Hamada, Kenji Tada, Yoshiki Saito, Masato Kochi, Jun-ichi Kuratsu and Yukitaka Ushio
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1354::AID-CNCR35>3.0.CO;2-R
Overexpression of tissue factor by pituitary adenoma cells may contribute to the development of vascular events, such as infarction and/or hemorrhagic infarction, in pituitary adenomas.
General Topic
Anemia: Erythropoietin
You have full text access to this OnlineOpen article
Erythropoietin reduces anemia and transfusions : A randomized trial with or without erythropoietin during chemotherapy (pages 1362–1367)Frank R. Dunphy, Bruce R. Harrison, Teresa L. Dunleavy, Jack J. Rodriguez, Jack G. Hilton and James H. Boyd
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1362::AID-CNCR36>3.0.CO;2-T
There was less anemia and fewer transfusions in patients randomized to receive erythropoietin during chemotherapy with paclitaxel and carboplatin.
Lymphoma, Cutaneous
You have full text access to this OnlineOpen article
Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma (pages 1368–1376)Gorgun Akpek, Howard K. Koh, Steven Bogen, Carl O'Hara and Francine M. Foss
Article first published online: 20 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8
Alternative treatment modalities are needed in patients with advanced cutaneous T-cell lymphoma (CTCL) including mycosis fungoides. In this study, combination chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone was found to be an effective treatment regimen in patients with recurrent and refractory CTCL.